AstraZeneca (AZN) has released an update.
AstraZeneca and Daiichi Sankyo’s Enhertu has shown promising results in a Phase III clinical trial, delivering a significant improvement in progression-free survival for patients with HR-positive, HER2-low metastatic breast cancer post-endocrine therapy. The data suggest Enhertu could redefine the standard of care for a broader patient population, potentially impacting 60-65% of HR-positive, HER2-negative breast cancer cases. The safety profile aligns with previous trials, and these findings are set to be presented at an upcoming medical meeting and discussed with global regulators.
For further insights into AZN stock, check out TipRanks’ Stock Analysis page.
